Research Grade Acazicolcept

Description: Acazicolcept (BS11214) is a research-grade recombinant antibody targeting CD28. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species:
Isotype: Fusion-[ICOSLGN-terminalfragment(1-122)]2-IGHG1Fc(Fragmentconstant)
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality:
Applications: Research Grade Biosimilar
Target: CD28,TP44,T-cell-specificsurfaceglycoproteinCD28,CD278,ICOS,InducibleT-cellcostimulator,Activation-induciblelymphocyteimmunomediatorymolecule,AILIM
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: ALPN-101,ICOSLvIgD-Fc,CAS:2270247-50-0
Background: Acazicolcept (ALPN-101), an Fc fusion protein, is a dual inducible T cell costimulator (ICOS)/CD28 antagonist. Acazicolcept has anti-inflammatory activities.
Note: For research use only. Not suitable for clinical or therapeutic use.